Ryvu Therapeutics and Menarini Group Amend Global Licensing Agreement for Dapolsertib Development

Ryvu Therapeutics has signed an amendment with the Menarini Group to adjust the clinical development strategy for the oncology drug candidate dapolsertib. The agreement modifies the scope of ongoing clinical trials, though specific financial terms or changes to the development timeline remain undisclosed. This shift reflects a strategic recalibration of the partnership's pipeline priorities.